Active, not recruitingPhase 1NCT06539338

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Studying Precursor B-cell acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kite, A Gilead Company
Principal Investigator
Kite Study Director
Kite, A Gilead Company
Intervention
INT2104(genetic)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06539338 on ClinicalTrials.gov

Other trials for Precursor B-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Precursor B-cell acute lymphoblastic leukemia

← Back to all trials